Bristol-Myers Squibb (BMY) Says Opdivo Now First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
